Multiple effects of α1-antitrypsin on breast carcinoma MDA-MB 468 cell growth and invasiveness
- 1 April 2003
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal Of Cancer Prevention
- Vol. 12 (2) , 117-124
- https://doi.org/10.1097/00008469-200304000-00005
Abstract
The degradation of extracellular matrix during cancer invasion results from the action of several protease and protease inhibitor systems. α1-Antitrypsin (AAT) is a serine proteinase inhibitor produced by various tumour cells, and its plasma concentration rises during inflammation, infection and malignant diseases. AAT is found in a native, inhibitory active form, but also in other, non-inhibitory forms including cleaved and/or degraded. To test a hypothesis that AAT dependent on its molecular form may have multiple effects on tumour cell behaviour, breast cancer cells, MDA-MB 468, were cultured alone or stimulated with a native AAT or its C-terminal fragment (C-36) at a concentration of 5 μmol/l for 2, 24 and 48 hours. Native AAT added to the cells for 2 hours enhanced transforming growth factor beta 1 (TGFβ1) levels by 50%, but inhibited cell proliferation (by 61%), reduced interleukin 6 (IL-6) levels (by 87%) and activity (by about 66%), compared with non-stimulated cells. Native AAT showed similar, but less pronounced, effects when added to the cells for 24 and 48 hours. Under the same experimental conditions the cells exposed to the C-36 peptide significantly increased in proliferation, invasiveness and showed higher IL-6 levels. In addition, cells treated with the C-36 for 48 hours increased in NFκB (nuclear factor kappa B) activity. These results indicate that AAT, dependent on its molecular form, can both suppress and induce breast tumour cell biological activity in vitro.Keywords
This publication has 63 references indexed in Scilit:
- Human monocyte activation by cleaved form of alpha‐1‐antitrypsinEuropean Journal of Biochemistry, 1999
- Tumor necrosis factor alpha-mediated inhibition of melanogenesis is dependent on nuclear factor kappa B activationOncogene, 1999
- Inhibition of human serine proteases by SPAAT, the C-terminal 44-residue peptide from α1-antitrypsinBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1997
- Immunochemical and functional properties of biliary alpha-1-antitrypsinScandinavian Journal of Clinical and Laboratory Investigation, 1996
- Human Colon Carcinoma Cells Synthesize and Secrete α1-Proteinase InhibitorBiological Chemistry Hoppe-Seyler, 1996
- Structure, Regulation and Function of NF-kappaBAnnual Review of Cell Biology, 1994
- Interaction of Matrix Metalloproteinases with Serine Protease InhibitorsAnnals of the New York Academy of Sciences, 1994
- Function and Activation of NF-kappaB in the Immune SystemAnnual Review of Immunology, 1994
- Identification of hydrophobic fragments of α1‐antitrypsin and Cl protease inhibitor in human bile, plasma and spleenFEBS Letters, 1992
- Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomasFEBS Letters, 1989